Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2005

View Archived Issues

Therapeutic benefits of NSC-631570 in xeroderma pigmentosum

Improved barrier function found with lubiprostone in ischemia-injured intestine

Itopride improves gastric emptying in diabetic patients with gastroparesis

Preliminary phase II data on the antiviral efficacy of BIVN-401 in chronic hepatitis C

Interim data support the use of IDEA-033 in chronic pain

Favorable pharmacokinetic profile reported for ALTU-238 in healthy volunteers

CP-432 restores and adds bone mass in ovariectomized osteopenic rats

L-2286 reveals the cardioprotective effects of PARP inhibition

Novel approach for SARS treatment via RNA interference

Minerval - a novel compound and a new anticancer therapeutic strategy

Colostrinin evokes normalization of mitochondrial function

Iron chelator facilitates neurorescue

Positive opinion for oral iron chelator Exjade

XTL-6865 begins phase Ia study for HCV

Lilly to update Strattera label following reports of suicidal thoughts

Dr. Reddy's enters agreement with Rheoscience for balaglitazone

Phase II results for APF-530

Sirna Therapeutics and Allergan form strategic ophthalmology alliance

Myriad Genetics discovers COB1 gene for early-onset obesity

Eisai assumes development of Dainippon's AS-3201 for diabetic neuropathy

Takeda enters into agreement for Merck's matuzumab

German approval for Plenaxis

Sonus initiates pivotal study for Tocosol Paclitaxel for metastatic breast cancer

Mixed topline results for milnacipran in fibromyalgia

Pivotal phase III study of tesmilifene for breast cancer completes enrollment

Enrollment completed in phase II trial of AGI-001 for functional dyspepsia

New treatments for cancer covered in recent patents

Agents for arthritis in early development

Similar effects found for etilevodopa and levodopa in PD patients with motor fluctuations

Good efficacy and safety profile reported for R-411 in patients with moderate asthma

Bristol-Myers Squibb patent describes novel therapeutic agents for sarcopenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...